Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.02 USD
-0.06 (-1.47%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $4.02 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Ironwood Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -1,031.56 | 175.07 | 528.45 | 106.18 | 21.51 |
Depreciation/Amortization & Depletion | 1.58 | 1.42 | 1.52 | 3.56 | 5.58 |
Net Change from Assets/Liabilities | 11.28 | 2.82 | 17.73 | -0.94 | -99.99 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 11.36 |
Other Operating Activities | 1,202.13 | 94.46 | -285.81 | 60.04 | 72.27 |
Net Cash From Operating Activities | 183.43 | 273.76 | 261.90 | 168.84 | 10.73 |
Property & Equipment | -0.27 | -0.14 | -0.27 | -1.84 | -6.92 |
Acquisition/ Disposition of Subsidiaries | -1,026.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -4.22 |
Net Cash from Investing Activities | -1,026.32 | -0.14 | -0.27 | -1.84 | -11.14 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -19.95 | -116.85 | -4.55 | 18.55 | -11.56 |
Issuance (Repayment) of Debt | 300.00 | -120.70 | 0.00 | 0.00 | 19.43 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.89 | 0.00 | 0.00 | 0.00 | -9.05 |
Net Cash from Financing Activities | 277.16 | -237.55 | -4.55 | 18.55 | -1.19 |
Effect of Exchange Rate Changes | -0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -565.78 | 36.07 | 257.08 | 185.54 | -1.60 |
Cash at Beginning of Period | 657.94 | 621.86 | 364.78 | 179.24 | 180.85 |
Cash at End of Period | 92.15 | 657.94 | 621.86 | 364.78 | 179.24 |
Diluted Net EPS | -6.45 | 0.96 | 3.21 | 0.66 | 0.14 |
Fiscal Year End for Ironwood Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -5.02 | -4.16 | -1,031.56 | -1,029.81 | -1,043.76 |
Depreciation/Amortization & Depletion | 1.02 | 0.51 | 1.58 | 1.06 | 0.56 |
Net Change from Assets/Liabilities | 44.98 | 33.58 | 11.28 | 19.82 | 24.57 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 37.47 | 15.06 | 1,202.13 | 1,156.52 | 1,133.77 |
Net Cash From Operating Activities | 78.45 | 44.99 | 183.43 | 147.59 | 115.13 |
Property & Equipment | -0.13 | -0.07 | -0.27 | -0.06 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -1,026.05 | -1,022.07 | -999.49 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.13 | -0.07 | -1,026.32 | -1,022.13 | -999.51 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 10.81 | 10.06 | -19.95 | 5.36 | 5.35 |
Issuance (Repayment) of Debt | -75.00 | -25.00 | 300.00 | 325.00 | 400.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.74 | -0.62 | -2.89 | -2.30 | -2.30 |
Net Cash from Financing Activities | -64.93 | -15.56 | 277.16 | 328.06 | 403.05 |
Effect of Exchange Rate Changes | -0.03 | 0.02 | -0.05 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 13.37 | 29.39 | -565.78 | -546.48 | -481.32 |
Cash at Beginning of Period | 92.15 | 92.15 | 657.94 | 657.94 | 657.94 |
Cash at End of Period | 105.52 | 121.54 | 92.15 | 111.46 | 176.62 |
Diluted Net EPS | -0.01 | -0.03 | 0.05 | 0.09 | -6.84 |